Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The FDA are moving closer to award full approval ( trial result dependent ) for a longeity drug for dogs, so highly significant for Genflow's GF-4001 Non-Human Pipeline Anti-aging for veterinary use (dogs) and every chance we could get confirmation of the planned Pivotal trial anti-aging for dogs and an announcement of a JV Veterinary partner. Gla ;-)
29/11/3
A San Francisco-based biotechnology firm is on a mission to keep your best friend around a little longer.
Loyal is spearheading the development of an experimental drug geared toward extending the lifespan of large-breed dogs by a minimum of one year. On Tuesday, it secured conditional approval for its medication from the U.S. Food and Drug Administration.
The landmark approval clears the way for more extensive clinical trials. It also marks the first time the agency has endorsed a longevity drug.
hTtps://www.sfchronicle.com/sf/article/s-f-startup-wants-help-dogs-live-longer-got-fda-18522309.php
I got a feeling we will all be reading this, jam tomorrow mid 2024
Time they were putting some meat on the bone
Looks like UK Biotech is hot hot hot this year and Genflow's tiny market cap looks extremely attractive commensurate to near term news and exciting prospects and potential going forward, in run up to human trials 2025!!! Gla :-)
Great rise, but this is nothing compared to what is to come!
GLA
Looking good and strong with news expected soon, which could add significant value. Gla holders :-)
Good to see a company so on point with its social media munch. I enjoy watching their LinkedIn updates, as well as seeing the calibre of industry experts who like their posts, affirming that Genf are seen as fellow industry leaders in the field of longevity.
I was thinking more about the relevance with SIRT6 and food. We spend a fortune every year buying produce because it says organically reared. What would people pay for meat such as cow and chickens, if they’re reared on SIRT6 nutrients, as we all know we are what we eat and surely consumers would be happy to pay a premium for food enrichment that could prolong a healthy lifespan?
GenFlow Biosciences
1,386 followers
13h
Investing in GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) offers a unique opportunity to support pioneering work in the longevity field. Our company focuses on developing novel therapeutics that target the aging process, including our lead compound GF-1002, which is based on a centenarian variant of the SIRT6 gene. This innovative approach aims to extend both healthspan and lifespan, addressing the global challenge of aging and its associated health and economic impacts.
Learn more here: hTtps://loom.ly/MeQymHs
#GENF #longevity #healthspan #SIRT6
Agree munch. The pharma market is off to a hot start for 2024, and the team have so much to showcase. The company has been operating under radar, but things certainly look set to change, especially as more and more people become obsessed with the maintenance of good health, as our population gets older and older.
Money- it’s about time to on all fronts. Huge appetite for bio companies just now.
GLA
Harley there is a group, if you go on twitter and type #genf you’ll be able to find it, as it won’t show the pathway here if I type it.
Cheers Porter, and full market interest can't be far off Northeast, and I'm sure Eric is ready to deliver a flow of positive news....the Biotech sector at long last could be ready for some serious UPside and market appreciation, judging by today's Top risers board and Genflow's tiny market offers tremendous UPside potential. Gl :-)
Is there a group??
Fantastic read. One day the market will get what we are all about
GLA
Lovely find Munch. May explain the sudden jump in share price.
Great to see the company being recognised as one to be watched for the life changing science it can offer!
The Gaurdian....Company to Watch 2024!!!
4th January 2024
Genflow Biosciences
Longevity is not just for billionaires, says Dr Eric Leire, the founder and chief executive of Genflow Biosciences, which in December 2022 became the first anti-ageing biotech to list in Europe.
The London-listed and headquartered company, which has its labs in Belgium and an office in Cambridge, Massachusetts, is developing gene therapies for longer, healthier lives.
The company’s work is based on a rare mutation of the SIRT6 gene found in people who live beyond the age of 100, which was discovered by Dr Vera Gorbunova’s team at the University of Rochester in 2019. She chairs Genflow’s scientific advisory board.
“Some people are lucky to have the good gene, and what we want to do is share that luck with everybody,” says Leire, who previously worked for Pfizer and Schering-Plough.
Genflow plans to test an experimental therapy on people with an age-related liver disease called NASH in early 2025. It is also developing a therapy for Werner syndrome, a rare accelerated ageing disease, by which SIRT6 messenger RNA delivers the gene to the skin. Genflow is also launching a programme to prevent age-related loss of muscle mass, funded by new research grants.
It started trading on the OTCQB venture market in the US in the summer, to expand its reach to US investors. As an early-stage biotech, Genflow is a risky investment; its London-listed shares have lost nearly 90% of their value in the first year of trading. But it is certainly one to watch. The longevity science sector is forecast to reach $2bn (£1.6bn) by 2030, according to Insight Analytics. Julia Kollewe
Much more to come Porter...A very Bright and Happy New Year!!! :-)
0 0 0
GenFlow Biosciences
1,380 followers
3m
GenFlow Biosciences (LSE: GENF) (OTCQB: GENFF) is thrilled to be named "a firm to watch" by the The Guardian today.
As clinical trials for patients suffering from NASH get underway in 2025, we are very excited for 2024 and beyond.
Read the article here: hTtps://loom.ly/PWx_em8 #GENF #longevity #healthspan #SIRT6 #smallcaps #companytowatch
Lovely start to the year Munch.
Also seeing some decent articles popping up on Longevity, with Phil Newman noting family offices have a particular interest in the sector.
The below article released yesterday also notes:
"In the third quarter of 2023, the US contributed to 65% of all deals in the longevity sector, a report revealed, but Europe is getting involved as well. France and Switzerland made up 23% of total deals, with the UK at 5%."
https://sifted.eu/articles/new-year-longer-life-what-longevity-has-to-offer-in-2024
I'm certainly glad to be invested before the ship departs :)
Get UP there!!! " A Bright New Year " ahead, with any Luck. In Eric we trust!!! ;-)
On and UP....it's been a while, hopefully in anticipation of a flow of imminent good news along with a significant re-rate or two....C'mon Eric....Gla holders..:-)
By rights, this should be at float or above.
It does seem like the CEO of GENFLOW does not seem to care about his shareholders, shame really as the science seems to be the future.
But
Why is the share price sitting just over a penny - it just does not make sense
He needs to be replaced by someone who has investors interests at heart and someone seasoned who can promote the science and the company to institutional investors.
Eric Leire seems to have gone to sleep- wakey wakey Eric where is the news and updates ?
If this was a horse it would be put out to graze
Yep, the slide in sp isn't great and has been very disappointing and so can't imagine Genflow posting such a message if they weren't going to back it up and expecting some good cheer....Gl :-)
I hope it’s a bright new year. Can’t get much worse than this.
GLA